- Poster presentation
- Open Access
German evidence and consensus based guidelines 2010 for the treatment of juvenile idiopathic arthritis (JIA)
Pediatric Rheumatology volume 9, Article number: P181 (2011)
To improve the quality of care for patients with JIA, standardization of treatment is mandatory. We present a clinical practice guideline (CPG) for the treatment of JIA. It is based on the existing CPG of 2005* and 2008# (*published as book chapter; #peer reviewed publication: Clinical Research and Practice in Paediatrics 2008; 220: 392 - 402).
We performed a systematic literature analysis in PubMed (deadline: 15th January 2010, terms "juvenile idiopathic (rheumatoid) arthritis", "therapy", limits: “humans”, “published in the last 3 years”, “all child 0-18 years”, “clinical trial”) and evaluated relevant studies for quality of methodology. A formal consensus process, i.e. Nominal group technique and Delphi method, was conducted at three moderated consensus conferences at Düsseldorf or Krefeld (Germany) on May 9th, 2007, August 1st, 2007 and January 15th, 2010. Conferences were attended by 95% of the representatives who had been nominated by their scientific society or organizations.
15 consensus statements and key notes regarding drug therapy, symptomatic and surgical management of JIA were compiled and judged strictly by the criteria of Evidence-Based Medicine (presented on the poster).
Currently, we recommend that JIA is treated with NSAR followed by local GC and/ or MTX as first line treatment. Other interventions e. g. the role of biologic agents, physiotherapy, and arthroscopy are discussed strictly on the basis of literature available. Our CPG will require a frequent update, as the number of randomized trials is increasing and the new potential drugs will become available.
About this article
Cite this article
Dueckers, G., Guellac, N., Arbogast, M. et al. German evidence and consensus based guidelines 2010 for the treatment of juvenile idiopathic arthritis (JIA). Pediatr Rheumatol 9, P181 (2011). https://doi.org/10.1186/1546-0096-9-S1-P181
- Juvenile Idiopathic Arthritis
- Clinical Practice Guideline
- Biologic Agent
- Scientific Society
- Consensus Statement